Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - PT009001

Study identifier:PT009001

ClinicalTrials.gov identifier:NCT02196077

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double Blind, Chronic Dosing (28 Days), Four Period, Five Treatment, Incomplete Block, Multi Center, Crossover Study to Assess the Efficacy and Safety of PT009, PT008, and PT005 in Subjects With Moderate to Severe COPD

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 2

Healthy volunteers

Study drug

BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg, BD MDI 320 μg, FF MDI 9.6 μg

Sex

All

Actual Enrollment

180

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 01 Aug 2014

Primary Completion Date: 01 Mar 2015

Study Completion Date: 01 Mar 2015

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2019 by Pearl Therapeutics, Inc.

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

-Informed Consent Form (ICF) prior to any study related procedures
-COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
-Tobacco Use: Current or former smokers with a history of at least 10 pack years of cigarette smoking
-Women of non-childbearing potential or medically acceptable contraception for women of child-bearing potential and males with female partners of childbearing potential
-Severity of Disease: Subjects with an established clinical history of COPD and severity defined as: FEV1/forced vital capacity (FVC) ratio of <0.70; At Screening (Visit 1a/b), post bronchodilator FEV1 must be <80% predicted normal value, calculated using NHANES III (Third National Health and Nutrition Examination Survey) reference equations; the measured FEV1 must also be ≥30% of predicted normal value; at Visit 2, the average of the 60 minutes and 30 minutes pre dose FEV1 assessments must be <80% predicted normal value calculated using NHANES III reference equations
-Screening clinical laboratory tests must be acceptable to the Investigator
-Screening ECG must be acceptable to the Investigator
-Chest x ray or computerized tomography (CT) scan within 6 months prior to Visit 1a must be acceptable to the Investigator.

Exclusion Criteria

-Significant diseases other than COPD, ie., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
-Pregnancy, nursing female subjects, or subjects trying to conceive, or not using medically acceptable form of contraception
-Asthma: Subjects who have a primary diagnosis of asthma (Note: Subjects with a prior history of asthma are eligible if COPD is currently their primary diagnosis).
-Alpha 1 Antitrypsin Deficiency: Subjects who have alpha 1 antitrypsin deficiency as the cause of COPD
-Active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, and uncontrolled sleep apnea (ie., in the opinion of the Investigator severity of the disorder would impact the conduct of the study)-
-Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study
-Poorly Controlled COPD
-History of ECG abnormalities
-Cancer not in complete remission for at least 5 years
-Clinically significant, symptomatic prostatic hypertrophy
-Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening
-Clinically significant bladder neck obstruction or urinary retention
-Inadequately treated glaucoma
-History of an allergic reaction or hypersensitivity to any drug or to any component of the formulations used in this study

No locations available

Arms	Assigned Interventions
Experimental: BFF MDI 320/9.6 μg Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)	Drug: BFF MDI 320/9.6 μg Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Experimental: BFF MDI 160/9.6 μg Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)	Drug: BFF MDI 160/9.6 μg Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Experimental: BFF MDI 80/9.6 μg Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)	Drug: BFF MDI 80/9.6 μg Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Experimental: BD MDI 320 μg Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)	Drug: BD MDI 320 μg Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
Experimental: FF MDI 9.6 μg Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)	Drug: FF MDI 9.6 μg Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4145&filename=PT009001-Protocol_Redacted_11APR2018.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Catherine Pelc

862-777-8058

[email protected]

Investigators

Principal Investigator

Shahid Siddiqui

Pearl Therapeutics, Inc.